Contents

Contributors xiii

Signal Sorting by G-Protein-Linked Receptors
Graeme Milligan

I. Introduction 1
II. G-Protein-Linked Receptors 2
III. Guanine Nucleotide-Binding Proteins 3
IV. Effectors 5
V. G-Protein α vs βγ Effects 6
   A. Background 6
   B. Phospholipase Cβ Regulation 6
   C. Adenylyl Cyclase Regulation 8
VI. Signal Sorting Defined by Selectivity in Receptor–G-Protein Interactions 9
VII. Splice Variation and the Regulation of Signal Sorting 15
    A. Receptor Splice Variants 15
    B. G-Protein Splice Variants 18
VIII. Signal Sorting: Information from Mutational Analysis 19
    A. Constitutive Activation of G-Protein-Linked Receptors 19
    B. Constitutive Activation of G-Proteins α Subunits 19
References 20
Regulation of Phospholipase A₂ Enzymes: Selective Inhibitors and Their Pharmacological Potential
Keith B. Glaser

I. Biochemistry of Phospholipase A₂ (PLA₂) Enzymes 31
   A. Nonpancreatic Secretory PLA₂ 33
   B. Cytosolic PLA₂ 35
   C. Inhibition Kinetics of PLA₂ 37

II. Inhibitors of PLA₂ 41
   A. Natural Product Inhibitors of PLA₂ 41
   B. Molecular Modeling Approach to PLA₂ Inhibitor Design 47
   C. Phospholipid Analogs as Inhibitors of PLA₂ 52
   D. Lipocortins to Antiflammins 54

III. Newer Approaches to Elucidation of Relevant PLA₂s 56
   A. Anti-sense cDNA for sPLA₂ 56
   B. Anti-sense cDNA for cPLA₂ 57
   C. Paracrine Functions of sPLA₂ and pPLA₂ 57

IV. Summary 58
    References 61

Platelet Activating Factor Antagonists
James B. Summers and Daniel H. Albert

I. Introduction 67
   A. PAF Structure and Biosynthesis 68
   B. PAF Receptors 71

II. PAF Receptor Antagonists 74
   A. Structural Analogs of PAF 74
   B. Pyrrolothiazole- and Thiazolidine-Related Antagonists 78
   C. Dihydropyridine Antagonists 82
   D. Imidazole-Containing Antagonists 84
   E. Furan-Containing Antagonists 86
   F. Hetrazepine Antagonists 91
   G. Miscellaneous Antagonists 97
   H. PAF Receptor Modeling 102

III. PAF Antagonists and Models of Human Disease 103
   A. PAF and Asthma 103
   B. Septic Shock 109
   C. Ischemia/Reperfusion Injury 120
   D. Pancreatitis 132

IV. Conclusions 136
    References 136
Pharmacological Management of Acute and Chronic Bronchial Asthma
Michael K. Gould and Thomas A. Raffin

I. Introduction 169
   A. Definition 169
   B. Prevalence and Mortality 170
   C. Costs 171
II. History of Asthma Therapy 171
   A. Ancient and Premodern Eras 171
   B. Modern Era 172
III. Pathophysiology of Asthma 173
   A. Functional Changes in the Airways 174
   B. Inflammatory Cells and Mediators 175
   C. Neurogenic Mechanisms 176
IV. Scientific Basis of Drug Therapy 176
   A. Bronchodilators 177
   B. Anti-inflammatory Agents 184
   C. Steroid-Sparing Agents 191
   D. Investigational Drugs 193
V. Clinical Effectiveness of Drug Therapy 193
VI. Recommendations for Pharmacological Management 194
References 195

Anti-Human Immunodeficiency Virus Immunoconjugates
Seth H. Pincus and Vladimir V. Tolstikov

I. Introduction 205
II. Immunoconjugate Structure 208
   A. Targeting Moiety 209
   B. Targeted Moiety 212
   C. Linkers 217
III. Antigenic Targets of Anti-HIV Immunoconjugates 217
   A. HIV Antigens 217
   B. Cellular Antigens 222
IV. The Use of Anti-HIV Immunoconjugates 223
   A. General Principles 223
   B. In Vitro Studies 224
   C. Pharmacologic Enhancement of Immunotoxin Action 228
   D. Clinical Studies 230
   E. Potential Problems 231
V. The Use of Immunotoxins to Study the Cell Biology of HIV Infection 233
Recent Advances in the Treatment of Human Immunodeficiency Virus Infections with Interferons and Other Biological Response Modifiers

Orjan Strannegård

I. Introduction 249
II. Natural Course of HIV Infection 250
III. Immune Response to HIV Infection 251
IV. Autoimmunity and Apoptosis 252
V. Production of Interferons and Other Cytokines in HIV Infection 253
   A. Interferons 253
   B. CD8-Derived Soluble Factor 255
   C. Tumor Necrosis Factor 255
   D. Other Cytokines 256
VI. Rationale for Treatment with Biological Response Modifiers 256
VII. Treatment with Interferon-α 257
   A. Asymptomatic HIV Infection 257
   B. Kaposi's Sarcoma 258
   C. Late Stage HIV Infection 259
   D. Combined Treatment with IFN-α and Zidovudine 259
   E. General Conclusions Regarding the Efficacy of IFN-α Therapy in HIV Infection 261
   F. Possible Reasons for Relative Failure of IFN-α Therapy 262
VIII. Treatment with Interferon-β 264
IX. Treatment with Interferon-γ 265
X. Treatment with Other Biological Response Modifiers 266
   A. Tumor Necrosis-α and TNF-α Inhibitory Drugs 266
   B. Hematopoietic Growth Factors 267
   C. N-Acetylcysteine and Other Antioxidants 268
   D. Isoprinosine 270
   E. Thymic Factors 271
   F. Interleukin-2 271
   G. Cyclosporin A and Corticosteroids 272
XI. Immunomodulatory Effects of Therapeutic, Specific Immunization 273
XII. Future Studies 273
XIII. Conclusions 275
References 276
Advances in Cancer Gene Therapy
Wei-Wei Zhang, Toshiyoshi Fujiwara, Elizabeth A. Grimm, and Jack A. Roth

I. Introduction 289
II. Current Approaches to Gene Transfer 290
   A. Nonviral Gene Delivery Systems 290
   B. Recombinant Virus-Mediated Gene Transfer 295
III. Genetic Sequence-Targeted Gene Therapy 300
   A. Antisense Oligonucleotides 301
   B. Antisense RNA 302
   C. Antigene Oligonucleotides 303
   D. Ribozymes 305
IV. Cytokine Gene Therapy and Tumor Vaccination 306
   A. Genetic Modulation of Lymphocytes 306
   B. Cytokine Gene-Modified Tumor Cell Vaccination 308
   C. Antigen Presentation Gene Modulation for Tumor Cell Vaccination 312
V. Toxin or Suicide Gene Therapy 314
   A. Toxin Gene Therapy 314
   B. Suicide Gene Therapy 315
VI. Drug-Resistance Gene Therapy 316
   A. Multidrug Resistance Gene and Other Chemoresistant Genes 316
   B. Chemoprotection 318
VII. TumorSuppressor Gene Therapy 319
   A. Tumor Suppressor Genes 320
   B. Tumor Suppressor Gene Therapy 321
VIII. Future Prospects 323
      References 324

Melanoma and Melanocytes: Pigmentation, Tumor Progression, and the Immune Response to Cancer
Setaluri Vijayasaradhi and Alan N. Houghton

I. Introduction 343
II. Biology of the Melanocyte 344
   A. Melanin Synthesis and Genes Determining Pigmentation 345
   B. Biogenesis of Melanosomes 348
III. Melanoma: Malignant Transformation of Melanocytes and Melanoma Progression 348
   A. Growth of Melanocytes and Melanoma 349
   B. Expression of Receptors for Growth Factors on Melanoma Cells 351
High-Density Lipoprotein Cholesterol, Plasma Triglyceride, and Coronary Heart Disease: Pathophysiology and Management

Wolfgang Patsch and Antonio M. Gotto, Jr.

I. Introduction 375
II. Plasma Lipids, Lipoproteins, and Apolipoproteins 376
III. Lipoprotein Metabolism 378
   A. Transport of Exogenous Lipids 378
   B. Transport of Endogenous Lipids 381
IV. Classification of Hypertriglyceridemias 384
   A. Primary Hypertriglyceridemias 385
   B. Secondary Hypertriglyceridemias 389
V. Disorders Affecting HDL Cholesterol Levels 390
VI. HDL Cholesterol, Plasma Triglycerides, and Risk for Coronary Heart Disease 393
VII. Management of Hypertriglyceridemia and Low HDL Cholesterol Levels 399
   A. Nicotinic Acid and Derivatives 403
   B. Fibric Acid Derivatives 406
   C. HMG-CoA Reductase Inhibitors 410
   D. Other Approved Drugs for the Management of Hyperlipidemia 412
   E. Fish Oil and Oxandrolone 413
      References 413
Neurotransmitter-like Actions of L-DOPA
Yoshimi Misu, Hiroshi Ueda, and Yoshio Goshima

I. Introduction 427
II. Transmitter-like Roles in the Striatum 429
   A. In Vitro and in Vivo Release of L-DOPA 429
   B. In Vitro Presynaptic Responses to Levodopa 433
   C. Structure-Activity Relationship for Levodopa 438
   D. In Vivo Postsynaptic Responses to Levodopa and L-DOPA 439
   E. Some Responses of Parkinson’s Model Rats to Levodopa 442
III. Transmitter-like Roles of L-DOPA in the Medulla Oblongata 443
   A. Basal L-DOPA Release 445
   B. Evoked L-DOPA Release 445
   C. Baroreceptor-Mediated L-DOPA Release in the NTS Area 446
   D. Postsynaptic Responses to Levodopa and L-DOPA 446
   E. Aortic Nerve Denervation and L-DOPA Immunoreactivities 448
IV. Responses to Levodopa in the Spinal Cord 449
V. Conclusion 450
   References 450

New Approaches to the Drug Treatment of Schizophrenia
Gavin P. Reynolds and Carole Czudek

I. Introduction 461
II. The Dopamine Hypothesis 463
III. Animal Behavioral Models for the Identification of Potential Antipsychotic Efficacy 465
   A. Dopaminergic Effects on Motor Function 465
   B. Conditioned Avoidance Response 467
   C. Latent Inhibition 468
   D. Prepulse Inhibition of the Startle Reflex 468
   E. The Hippocampal Lesion 469
IV. Dopamine D_2 Receptor Antagonists 469
   A. Antipsychotic Effects and Extrapyramidal Symptoms 472
   B. Tardive Dyskinesia 472
   C. Partial D_2 Agonists 472
V. Other Receptor Sites of Antipsychotic Action: The Clozapine Model 475
VI. Dopamine D_1 Receptors 476
Membrane Trafficking in Nerve Terminals

Flavia Valtorta and Fabio Benfenati

I. Introduction 505
II. Anatomical Organization of the Nerve Terminals 506
III. Biogenesis of Small Synaptic Vesicles 509
IV. Loading Synaptic Vesicles with Neurotransmitters 511
V. Exocytosis of Synaptic Vesicles: Preparatory Steps 514
VI. Exocytosis of Synaptic Vesicles: Mechanisms of Fusion 519
   A. Biophysical Aspects of Membrane Aggregation and Fusion 519
   B. Fusion Proteins and Fusion Pores 521
   C. Fusion Machines 525
VII. Recycling of Synaptic Vesicles 527
VIII. Life Cycle of Large Dense-Core Vesicles 532
IX. The Complex Role of Ca^{2+} in Neuronal Secretion 533
X. Plasticity of Secretory Mechanisms 535
XI. Neurotoxins Affecting Membrane Trafficking 540
   A. α-Latrotoxin 540
   B. Clostridial Neurotoxins 543
XII. Conclusions 545
   References 545

Index 559

Contents of Previous Volumes 571